Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

Sponsor
University Hospital, Strasbourg, France
Study ID
NCT07342920
Status
Recruiting
Apply to this trial

Conditions

  • Cystic Fibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Key Dates

First listed
Jan 15, 2026
Start date
Oct 15, 2025
Status verified
Jan 2026
Primary completion
Oct 31, 2026
Completion
Oct 15, 2026

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Prevalence of smoking in adults with cystic fibrosis [ Time Frame: Up to 12 months ]

Central Contacts

Related Studies